# PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

> **NCT04711434** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 260 (estimated)

## Conditions studied

- Lynch Syndrome

## Interventions

- **DRUG:** PD-1 Antibody

## Key facts

- **NCT ID:** NCT04711434
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2021-01-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04711434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04711434, "PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04711434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*